Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 257
- Registration Number
- NCT03272477
- Locations
- 🇩🇪
Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany
Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 384
- Registration Number
- NCT03123770
- Locations
- 🇨🇳
Cancer institute, Hangzhou, Zhejiang, China
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
- Conditions
- Interventions
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1174
- Registration Number
- NCT03036488
- Locations
- 🇦🇺
Royal Adelaide Hospital ( Site 2008), Adelaide, South Australia, Australia
🇺🇸Cedars Sinai Medical Center ( Site 0091), Los Angeles, California, United States
🇺🇸The University of Chicago Medical Center ( Site 0047), Chicago, Illinois, United States
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 503
- Registration Number
- NCT03013504
- Locations
- 🇧🇾
Minsk Clinical Oncological Dispensary, Minsk, Belarus
🇪🇸Hospital Universitario Virgen Macarena, Sevilla, Spain
🇮🇹Modena Hospital, Modena, Italy
PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Shi Yanxia
- Target Recruit Count
- 320
- Registration Number
- NCT03006614
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02987244
- Locations
- 🇨🇳
Peking Union medical college hospital, Beijing, Beijing, China
🇨🇳Tianjin medical universty cancer institute & hospital, Tianjin, Tianjin, China
Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 253
- Registration Number
- NCT02971345
- Locations
- 🇨🇳
Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 40
- Registration Number
- NCT02949258
- Locations
- 🇨🇳
Research institue of general surgery, Jinling hospital, Nanjing, Jiangsu, China
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2022-04-20
- Target Recruit Count
- 170
- Registration Number
- NCT02897050
- Locations
- 🇨🇳
Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
🇨🇳Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 290
- Registration Number
- NCT02879513
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.